MA28215A1 - Galenic forms of oxycodone controlled release for once-daily oral administration - Google Patents

Galenic forms of oxycodone controlled release for once-daily oral administration

Info

Publication number
MA28215A1
MA28215A1 MA28979A MA28979A MA28215A1 MA 28215 A1 MA28215 A1 MA 28215A1 MA 28979 A MA28979 A MA 28979A MA 28979 A MA28979 A MA 28979A MA 28215 A1 MA28215 A1 MA 28215A1
Authority
MA
Morocco
Prior art keywords
profiles
once
galenic forms
oral administration
controlled release
Prior art date
Application number
MA28979A
Other languages
French (fr)
Inventor
Stephen Hwang
Nishit B Modi
Padmaja Shivanand
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of MA28215A1 publication Critical patent/MA28215A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

FORMES GALÉNIQUES DE L'OXYCODONE À LIBÉRATION CONTRÔLÉE POUR ADMINISTRATION ORALE UNE FOIS PAR JOUR La présente invention concerne des formulations d'oxycodone qui produisent des profils plasma tiques en équilibre dynamique in vivo pratiquement plats. Les niveaux de tolérance associés à de tels profils et les niveaux de tolérance associés aux profils biphasiques se sont révélés ne pas être statistiquement différents. Les profils p.iasmatiques en équilibre dynamique in vivo pratiquement plats sont produits par des formes galéniques ayant des profils de libération in vit.ro pratiquement de l'ordre de zéro. De tels prot ils de libération produisent des niveaux faibles de Cmaz in vivo avec une dose unique qui peuvent diminuer la probabilité des effets secondaires néfastes.The present invention relates to oxycodone formulations that produce substantially in vivo dynamic equilibrium plasma profiles in practically flat equilibrium. The tolerance levels associated with such profiles and the tolerance levels associated with biphasic profiles have been shown not to be statistically different. The substantially in vivo dynamic equilibrium p.iasmatic profiles are produced by galenic forms having in vitro release profiles of substantially zero order. Such release proteins produce low levels of Cmaz in vivo with a single dose that may decrease the likelihood of adverse side effects.

MA28979A 2003-10-29 2006-04-28 Galenic forms of oxycodone controlled release for once-daily oral administration MA28215A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
MA28215A1 true MA28215A1 (en) 2006-10-02

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28979A MA28215A1 (en) 2003-10-29 2006-04-28 Galenic forms of oxycodone controlled release for once-daily oral administration

Country Status (14)

Country Link
EP (1) EP1677798A2 (en)
JP (1) JP2007509979A (en)
KR (1) KR20060108690A (en)
CN (1) CN1933837A (en)
AU (1) AU2004285547A1 (en)
BR (1) BRPI0415639A (en)
CA (1) CA2546691A1 (en)
EC (1) ECSP066534A (en)
IL (1) IL175193A0 (en)
MA (1) MA28215A1 (en)
NO (1) NO20062398L (en)
RU (1) RU2006118323A (en)
WO (1) WO2005041968A2 (en)
ZA (1) ZA200604310B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120050528A (en) 1999-10-29 2012-05-18 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102004032051A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
JP2011511782A (en) 2008-02-12 2011-04-14 アボット・ラボラトリーズ Extended release hydrocodone acetaminophen and related methods and uses
CA2723438C (en) 2008-05-09 2016-10-11 Gruenenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
ES2560210T3 (en) 2009-07-22 2016-02-17 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opiates
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CA2832436C (en) * 2010-04-07 2018-08-14 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
BR112013005194A2 (en) 2010-09-02 2016-05-03 Gruenenthal Gmbh tamper-resistant dosage form comprising inorganic salt
WO2013017242A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
PT2736495T (en) 2011-07-29 2017-11-30 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AR090695A1 (en) 2012-04-18 2014-12-03 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM RESISTANT TO ADULTERATION AND RESISTANT TO IMMEDIATE RELEASE OF DOSE
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (en) 2013-05-29 2017-07-25 Gruenenthal Gmbh tamper-proof dosage form containing one or more particles
JP6449871B2 (en) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Anti-modified dosage form containing ethylene-vinyl acetate polymer
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
BR112017021475A2 (en) 2015-04-24 2018-07-10 Gruenenthal Gmbh tamper-resistant dosage form with immediate release and resistance to solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6875501B2 (en) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト A pharmaceutical composition comprising an Akt protein kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
BR0304960A (en) * 2002-05-31 2005-01-04 Alza Corp Dosage forms and compositions for osmotic release of varying dosages of oxycodone

Also Published As

Publication number Publication date
NO20062398L (en) 2006-07-27
WO2005041968A2 (en) 2005-05-12
CN1933837A (en) 2007-03-21
KR20060108690A (en) 2006-10-18
ECSP066534A (en) 2006-11-24
IL175193A0 (en) 2008-04-13
CA2546691A1 (en) 2005-05-12
BRPI0415639A (en) 2006-12-12
AU2004285547A1 (en) 2005-05-12
EP1677798A2 (en) 2006-07-12
ZA200604310B (en) 2007-11-28
WO2005041968A3 (en) 2006-06-22
RU2006118323A (en) 2007-12-10
JP2007509979A (en) 2007-04-19

Similar Documents

Publication Publication Date Title
MA28215A1 (en) Galenic forms of oxycodone controlled release for once-daily oral administration
MA38576A1 (en) Colchicine extended-release formulations and methods of using the same
RS20110564A2 (en) Diurnal formulation of oxycodone
WO2004054581A3 (en) Cyclohexyl compounds as ccr5 antagonists
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
EP1820503A3 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
MA29273B1 (en) SYNERGISTIC COMBINATION OF XOLAIR / OMALIZUMAB / E25 AND AN IMMUNOSUPPRESSEUR AGENT
WO2002080969A1 (en) Remedies for infant chronic arthritis-relating diseases
CY1105648T1 (en) FILBANSERIN FOR THE TREATMENT OF EXTRAPYRAMIDAL MOVEMENT DISORDERS
AU2003215586A1 (en) Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa
ATE407928T1 (en) AMINO-PHTALAZINONE DERIVATIVES, USE AS KINASE INHIBITORS, PRODUCTION AND PHARMACEUTICAL COMPOSITION
MA31668B1 (en) POLYPEPTIDES, VARIOUS DOMAINS OF ANTIBODIES AND ANTAGONISTS
MXPA04003666A (en) Use of flibanserin in the treatment of sexual disorders.
TNSN07476A1 (en) N- (PYRIDINE -2- YL) - SULFONAMIDE DERIVATIVES
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
AU2003296992A1 (en) Pyrrolidine and azetidine compounds as ccr5 antagonists
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MX2007006558A (en) Topical nepafenac formulations.
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
HRP20080612T3 (en) Combination of tenofovir, ritonavir and tmc114
MA29278B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN INDOLYLMALEIMIDE DERIVATIVE
WO2007075572A3 (en) Orally active purine-based inhibitors of heat shock protein 90
WO2004064757A3 (en) Absorption enhancing agents
JP2008540405A5 (en)
DK1653923T3 (en) Oral delivery system comprising a biliary foam